Introduction to Antithrombin III
Antithrombin III (AT III) is a crucial biologic drug used to prevent and treat thromboembolic disorders, particularly in patients with hereditary antithrombin deficiency. This protein plays a vital role in regulating blood clotting and is derived from human plasma.
Market Size and Growth
The global Antithrombin III testing market is projected to experience significant growth over the coming years. By 2029, the market is expected to reach nearly $863.91 million, growing at a Compound Annual Growth Rate (CAGR) of 4.2% during the forecast period from 2023 to 2029. In 2022, the market size was valued at $647.73 million[1].
Key Drivers of Market Growth
Increasing Surgical Procedures
The rise in the number of surgeries performed globally is a major driver for the Antithrombin III market. Antithrombin III is often used in patients undergoing heart surgery and other procedures to prevent thromboembolism[1].
Growing Incidence of Health Conditions
The increasing incidence of health conditions such as septic shock and clotting disorders is another significant factor. For instance, around 900,000 people develop blood clots every year in the United States, resulting in approximately 100,000 deaths annually, according to the American Society of Hematology[1].
Technological Advancements
Advancements in technology for the production of Antithrombin III testing equipment and drugs are propelling the market forward. New dosing strategies and restriction criteria can also lead to significant cost savings, as seen in studies where implementing these strategies resulted in estimated annual savings of $556,000[2].
Increasing Protein Deficiency
The growing deficiency of proteins, particularly antithrombin, among the population is driving the demand for Antithrombin III. Approximately 1 in every 2,000 people globally suffers from antithrombin deficiency, making this a critical market segment[1].
Market Segmentation
By Application
The therapeutic segment dominates the Antithrombin III market, accounting for 95% of the market share in 2018. Antithrombin III is used as a therapy in various circumstances, including heart surgery and genetic disorders such as Antithrombin Deficiency[1].
By Dosage Form
The market is segmented into lyophilized and liquid forms. The choice of dosage form depends on the specific clinical needs and the convenience of administration[1].
By Sources
Antithrombin III can be derived from humans, goat milk, and other sources. Human-derived Antithrombin III is particularly popular due to its efficacy and safety profile[1].
Regional Insights
Asia Pacific
The Asia Pacific region, including countries like India and China, is growing rapidly due to increasing healthcare spending and the development of new treatment procedures. This region accounted for $179 million in 2018 and is expected to continue its rapid growth[1].
Europe
Europe is another significant market, driven by the adoption of human-based Antithrombin III products in countries such as France, Germany, and the UK. The launch of new Antithrombin III testing techniques by key players is expected to further boost the market in this region[1].
North America
North America is anticipated to hold the largest market share during the forecast period, driven by an increase in blood-related disorders and the frequent use of Antithrombin III testing. The region's government investments in healthcare infrastructure also contribute to this growth[1].
Key Players and Market Competition
Companies such as Shire, CSL Behring, and Grifols are prominent players in the Antithrombin III market. These companies are investing heavily in the development of new products and technologies, which is driving market growth[4].
Challenges and Restraints
High Cost and Regulatory Hurdles
The high cost of Antithrombin III activities and the availability of various alternatives in the market are significant restraints. Additionally, strict regulations and protests by animal welfare institutions against animal testing of new drugs further hamper market growth[1].
Cost-Saving Opportunities
Studies have shown that implementing restriction criteria and new dosing strategies can result in significant cost savings. For example, a study at The Johns Hopkins Hospital found that such strategies could save approximately $556,000 annually[2].
Clinical Use and Efficacy
THROMBATE III
THROMBATE III, a human plasma-derived Antithrombin III, is an effective choice for patients with hereditary antithrombin deficiency. It is indicated for the treatment and prevention of thromboembolism, including before, during, and after surgery and childbirth. Clinical studies have shown that THROMBATE III enhances the anticoagulant effect of heparin and has a low risk of major bleeding complications[5].
Adverse Reactions and Monitoring
Common adverse reactions to THROMBATE III include dizziness, chest discomfort, nausea, dysgeusia, and pain. It is crucial to monitor plasma AT levels frequently, especially in conditions such as surgery, hemorrhage, or acute thrombosis, and during intravenous heparin administration[5].
Financial Trajectory
The financial trajectory of the Antithrombin III market is promising, with a projected CAGR of 4.2% from 2023 to 2029. The market size is expected to grow from $647.73 million in 2022 to $863.91 million by 2029. This growth is driven by increasing demand, technological advancements, and investments by key players[1].
Key Takeaways
- The global Antithrombin III testing market is expected to reach $863.91 million by 2029, growing at a CAGR of 4.2%.
- Key drivers include the rise in surgical procedures, growing incidence of health conditions, and technological advancements.
- The therapeutic segment dominates the market, with human-derived Antithrombin III being the most popular.
- Asia Pacific and Europe are significant regions, with North America expected to hold the largest market share.
- High costs and regulatory hurdles are major restraints, but cost-saving strategies and new dosing techniques can mitigate these issues.
FAQs
What is the primary use of Antithrombin III?
Antithrombin III is primarily used to prevent and treat thromboembolic disorders, especially in patients with hereditary antithrombin deficiency.
Which region is expected to grow the fastest in the Antithrombin III market?
The Asia Pacific region is anticipated to emerge as the fastest-growing region due to increasing healthcare spending and the development of new treatment procedures.
What are the common adverse reactions to THROMBATE III?
Common adverse reactions include dizziness, chest discomfort, nausea, dysgeusia, and pain.
How can cost savings be achieved in the use of Antithrombin III?
Implementing restriction criteria and new dosing strategies can result in significant cost savings, as seen in studies where such strategies saved approximately $556,000 annually.
Which companies are prominent players in the Antithrombin III market?
Companies such as Shire, CSL Behring, and Grifols are prominent players in the Antithrombin III market.
Sources
- Maximize Market Research: Global Anti-Thrombin III Testing Market: Industry Analysis and Forecast.
- PubMed: Identification of Cost-Saving Opportunities for the Use of Antithrombin III.
- SAGE Journals: Issues in the Diagnosis and Management of Hereditary Antithrombin Deficiency.
- Fortune Business Insights: Antithrombin Market Size, Share, Trends & Growth | Global Report.
- THROMBATE III Official HCP Site: THROMBATE III (antithrombin III [human]).
